Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]

Adrian van den Hoven, Director General, Medicines for Europe

#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]